Treatment strategy in adrenocortical carcinomasFase II trial with docetaxel and cisplatin in patients with locally advanced or disseminated adrenocortical carcinomas
Phase 1
- Conditions
- Fase II trial of taxotere and cisplatin in patients with advanced or metastatic adrenocortical carcinoma
- Registration Number
- EUCTR2005-001341-42-DK
- Lead Sponsor
- Rigshospitalet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
Adrenocortical carcinoma
no possibility for operation
age > 18 years
performance 0 or 1
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
performance 2 or less
other cancer diseases
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method